Danish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
hemangioblastoma/træthed
Linket gemmes på udklipsholderen
4 resultater
Von hippel-lindau syndrome: diagnosis and management of hemangioblastoma and pheochromocytoma.
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
Introduction. Von Hippel-Lindau (VHL) syndrome is a pathological condition that causes various clinical symptoms and is difficult to diagnose. The most common pathological lesions are hemangioblastomas of the central nervous system, retinal angiomas, renal clear cell carcinomas, and
Systemic Sunitinib Malate Treatment for Advanced Juxtapapillary Retinal Hemangioblastomas Associated with von Hippel-Lindau Disease.
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
OBJECTIVE
To describe the clinical course of advanced juxtapapillary retinal capillary hemangioblastomas (RCH) associated with von Hippel-Lindau (VHL) disease treated with systemic sunitinib malate, an agent that inhibits both anti-vascular endothelial growth factor and anti-platelet-derived growth
The Efficacy and Safety of Tyrosine Kinase Inhibitors for Von Hippel-Lindau Disease: A Retrospective Study of 32 Patients.
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
Background: Von Hippel-Lindau (VHL) disease is an autosomal-dominant hereditary cancer syndrome. Currently, studies on tyrosine kinase inhibitor (TKI) therapy for VHL disease are scarce. In this study, we retrospectively evaluated the efficacy and safety of four TKIs in patients with VHL
Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
BACKGROUND
Von Hippel-Lindau (VHL) disease induces vascular neoplasms in multiple organs. We evaluated the safety and efficacy of sunitinib in VHL patients and examined the expression of candidate receptors in archived tissue.
METHODS
Patients with VHL were given four cycles of 50 mg sunitinib daily
Den mest komplette database med medicinske urter understøttet af videnskab
- Arbejder på 55 sprog
- Urtekurer, der understøttes af videnskab
- Urtegenkendelse ved billede
- Interaktivt GPS-kort - tag urter på stedet (kommer snart)
- Læs videnskabelige publikationer relateret til din søgning
- Søg medicinske urter efter deres virkninger
- Organiser dine interesser og hold dig opdateret med nyhedsundersøgelser, kliniske forsøg og patenter
Skriv et symptom eller en sygdom, og læs om urter, der kan hjælpe, skriv en urt og se sygdomme og symptomer, den bruges mod.
* Al information er baseret på offentliggjort videnskabelig forskning
